132281-59-5Relevant articles and documents
Discovery and process development of a novel TACE inhibitor for the topical treatment of psoriasis
Boiteau, Jean-Guy,Ouvry, Gilles,Arlabosse, Jean-Marie,Astri, Stéphanie,Beillard, Audrey,Bhurruth-Alcor, Yushma,Bonnary, Laetitia,Bouix-Peter, Claire,Bouquet, Karine,Bourotte, Marilyne,Cardinaud, Isabelle,Comino, Catherine,Deprez, Beno?t,Duvert, Denis,Féret, Angélique,Hacini-Rachinel, Feriel,Harris, Craig S.,Luzy, Anne-Pascale,Mathieu, Arnaud,Millois, Corinne,Orsini, Nicolas,Pascau, Jonathan,Pinto, Artur,Piwnica, David,Polge, Ga?lle,Reitz, Arnaud,Reversé, Kevin,Rodeville, Nicolas,Rossio, Patricia,Spiesse, Delphine,Tabet, Samuel,Taquet, Nathalie,Tomas, Lo?c,Vial, Emmanuel,Hennequin, Laurent F.
, p. 945 - 956 (2018)
Targeting the TNFα pathway is a validated approach to the treatment of psoriasis. In this pathway, TACE stands out as a druggable target and has been the focus of in-house research programs. In this article, we present the discovery of clinical candidate
Nuclear Magnetic Resonance Studies of Complexes of Aluminium(III), Gallium(III), and Indium(III) with Disulphonated 2,2'-Dihydroxyazobenzene Ligands in Aqueous Solution
Evans, Dennis F.,Iki, Nobuhiko
, p. 3773 - 3779 (2007/10/02)
Proton n.m.r. spectra are reported for complexes of AlIII, GaIII, and InIII with a variety of 5,5'-disulphonated 2,2'-dihydroxyazobenzenes in D2O solution.Ligand exchange is slow on an n.m.r. time-scale, and both 1:1 and 1